Rising Prevalence Of Type 2 Diabetes Driving Growth In The Market Due To Increasing Obesity And Demand For Effective Blood Sugar Management Driving Market Acceleration in the Oral Hypoglycemic Agents Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Oral Hypoglycemic Agents Market Size By 2025?
There has been a consistent increase in the market size of oral hypoglycemic agents recently. From $57.04 billion in 2024, it is projected to expand to $59.57 billion in 2025 with a compound annual growth rate (CAGR) of 4.4%. The historical growth is attributable to the increasing number of type 2 diabetes cases, the aging population, improved awareness of diabetes management, expanding healthcare access in developing markets, and the favorability of oral therapies over injectable ones.

How Big Is the Oral Hypoglycemic Agents Market Size Expected to Grow by 2029?
In the next few years, the oral hypoglycemic agents market is forecasted to experience consistent growth, expected to reach "$72.09 billion by 2029 with a compound annual growth rate (CAGR) of 4.9%. The anticipated growth during the forecasting period is linked to several key factors: an increased need for combination therapies, beneficial government healthcare policies, a rise in the utilization of telemedicine for diabetic care, an upswing in R&D investment for diabetes solutions, and a heightened emphasis on individualized diabetes treatment. Noteworthy trends for the forecast period include the creation of innovative oral antidiabetics, the development of fixed-dose combinations, advancements in pharmaceutical formulation, a concentrated effort to minimize drug side effects, and the inclusion of digital health instruments for monitoring glucose levels.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-hypoglycemic-agents-global-market-report

Which Key Market Drivers Powering Oral Hypoglycemic Agents Market Expansion and Growth?
The escalation in the occurrence of type 2 diabetes is forecasted to drive the expansion of the oral hypoglycemic agents market. Type 2 diabetes is a chronic metabolic disorder where the body fails to effectively utilize insulin, resulting in increased blood sugar levels. An increased adoption of inactive lifestyles, which notably diminish physical activity and lead to obesity and insulin resistance, are contributing factors to the rise in type 2 diabetes. Oral hypoglycemic agents manage type 2 diabetes by reducing blood sugar levels through diverse processes, such as promoting insulin sensitivity, stimulating insulin excretion, or lessening glucose absorption. For example, in April 2025, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported that about 589 million adults aged 20-79 globally are battling diabetes, and this figure is estimated to considerably soar to 853 million by 2050. Consequently, the escalating prevalence of type 2 diabetes is a major driver in the growth of the oral hypoglycemic agents market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24347&type=smp

Which Emerging Trends Are Transforming the Oral Hypoglycemic Agents Market in 2025?
Key players in the oral hypoglycemic agents market are directing their efforts towards the creation of sophisticated therapeutic remedies such as dipeptidyl peptidase-4 (DPP-4) inhibitors to enhance the regulation of blood sugar levels in Type 2 diabetes patients. DPP-4 inhibitors, a class of Type 2 diabetes drugs, work by increasing incretin hormone levels, which aids the body in insulin production, resulting in lower blood glucose levels. For example, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a pharmaceutical corporation based in China, garnered approval for their novel oral hypoglycemic drug, Sitagliptin Phosphate tablets, catered to effectively manage Type 2 diabetes. This offering works by suppressing the DPP-4 enzyme, thus aiding in the control of blood sugar levels. This release symbolizes Ganlee Pharmaceuticals' induction in the generic drug market, providing a financially viable solution for Type 2 diabetes management.

What Are the Emerging Segments in the Oral Hypoglycemic Agents Market?
The oral hypoglycemic agents market covered in this report is segmented -

1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy
2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations
3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities
5) By End users: Hospitals, Clinics

Subsegments:
1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24347&type=smp

Who Are the Global Leaders in the Oral Hypoglycemic Agents Market?
Major companies operating in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.

Which are the Top Profitable Regional Markets for the Oral Hypoglycemic Agents Industry?
North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24347

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay,
Americas: +1 310-496-7795,
Asia: +44 7882 955267 & +91 8897263534,
Europe: +44 7882 955267,
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.